Harvard Apparatus Regenerative Technology Inc

OTCQB:HRGNUnited States

Harvard Apparatus Regenerative Technology, Inc. is a clinical-stage biotechnology company. It uses the patient’s own stem cells grown on a porous plastic tubular scaffold to regenerate the esophagus after it has been removed due to cancer, trauma, or birth defects. The Company is targeting the conditions of the esophagus, including traumatic injury, caustic burns, tissue damage following chemoradiation therapy and birth defects. Its additional product candidates in its development pipeline are targeted at the reconstruction of the colon and uterus wound repair. Its product candidate includes Cellspan Esophageal Implant, and Cellspan Bronchial Implants. It is developing Cellspan Esophageal Implant for the treatment of esophageal atresia. Esophageal atresia is a birth disorder of the digestive system in which the esophagus does not develop properly. Cellspan Bronchial Implants enables the surgeon to preserve the lung and repair the bronchus through various surgical resection.

Contact Information

Headquarters

84 October Hill Road, Suite 11HOLLISTON, MA, United States 01746

Phone

774-233-7300

Fax

774-233-7302

Executives

Chairman of the Board, Chief Executive Officer

Junli He

President

Hong Yu

Vice Chairman of the Board

Jason Jing Chen

Chief Financial Officer

Joseph Damasio

Chief Scientific Officer

William Fodor